OAM
ADVM

Oxford Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

Oxford Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,336
Closed -$326K – 1627
2018
Q4 		$326K Buy
10,336
+2,611
+34% +$106K 0.01% 1370
2018
Q3 		$466K Sell
7,725
-13,454
-64% -$756K 0.01% 1334
2018
Q2 		$1.13M Sell
21,179
-5,902
-22% -$355K 0.02% 969
2018
Q1 		$1.57M Buy
27,081
+23,182
+595% +$1.44M 0.03% 704
2017
Q4 		$138K Sell
3,899
-15,845
-80% -$521K ﹤0.01% 1498
2017
Q3 		$703K Sell
19,744
-3,223
-14% -$89.4K 0.01% 1091
2017
Q2 		$574K Buy
22,967
+20,163
+719% +$551K 0.01% 1064
2017
Q1 		$76K Buy
2,804
+1,589
+131% +$45.2K ﹤0.01% 1365
2016
Q4 		$35K Buy
+1,215
New +$39.7K ﹤0.01% 748
2016
Q3 		– Sell
-6,048
Closed -$191K – 763
2016
Q2 		$191K Sell
6,048
-3,871
-39% -$175K 0.01% 697
2016
Q1 		$513K Sell
9,919
-26,359
-73% -$1.47M 0.01% 610
2015
Q4 		$3.45M Buy
+36,278
New +$3.19M 0.08% 274

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Oxford Asset Management's ADVM Position: Q1 2019 in Review

Oxford Asset Management sold out of Adverum Biotechnologies (ADVM) in Q1 2019, closing a stake of 10,336 shares — an estimated $326K sold.

Oxford Asset Management first reported a position in ADVM in Q4 2015 and held it in 12 quarters. The position peaked at $3.45M in Q4 2015. 83 funds tracked by Wall St. Rank hold ADVM as of Q1 2019.

  • Oxford Asset Management reported no remaining Adverum Biotechnologies position as of Q1 2019 after selling out during the quarter.
  • Oxford Asset Management sold 10,336 Adverum Biotechnologies shares in Q1 2019, an estimated $326K.
  • Oxford Asset Management first reported a position in Adverum Biotechnologies in Q4 2015 and held it in 12 quarters.
  • Oxford Asset Management's Adverum Biotechnologies position peaked at $3.45M in Q4 2015.
  • 83 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.